Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Sponsor: Department of Health and Human Services
This PHASE3 trial investigates Abdominal Infection and Acute Pyelonephritis and is currently completed. Department of Health and Human Services leads this study, which shows 14 recorded versions since 2014 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE3
▶ Show 9 earlier versions
-
Apr 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2019 — Apr 2019 [monthly]
Completed PHASE3
-
Jul 2018 — Jan 2019 [monthly]
Completed PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Aug 2017 — Mar 2018 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
May 2017 — Aug 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — May 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Department of Health and Human Services
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
For direct contact, visit the study record on ClinicalTrials.gov .